Rochester, NY (PRWEB) August 29, 2012
iCardiac Technologies, Inc., a leading global provider of cardiac safety assessment services, announced today that the company has achieved the industry’s lowest ECG query rates through the newly deployed iClinica 4G ECG data management platform. The benefits of low query rates include a faster database lock in global multi-site ECG studies, higher data quality, and improved economics of centralization of ECG data in late phase cardiac safety studies.
In late phase clinical trials, traditionally as much as 30% to 40% of ECG data have required queries. For a study with 30,000 ECGs, this may entail as many as 12,000 queries. It has been estimated that each individual query costs $30 to $80 to resolve, dramatically adding to the total cost of conducting a study and also delaying drug approval. iCardiac is able to achieve query rates in the single digits, which in comparison with available published industry reports places iCardiac as the industry leader in enabling the lowest query rates. This industry-leading capability provides significant cost and time savings.
“iCardiac’s dedication to continually improving cardiac safety assessment methods yet again delivers significant incremental value to our customers,” said Mikael Totterman, chief executive officer of iCardiac. “By combining cutting-edge software development with a strong understanding of drug developers’ needs, we are able to improve the efficiency of clinical trials.”
The company now serves 7 of the world’s 10 largest pharmaceutical sponsors, as well as numerous medium and small biotech, pharmaceutical and medical device clients.
iCardiac Technologies is a global cardiac safety company that has commercialized advanced research originating at leading academic institutions and pharmaceutical companies. Its reach is international, working with pharmaceutical and medical device clients all over the world to bring the best results to cardiac safety. For more information visit: http://www.icardiac.com/.